These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 9778664)
1. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Gao XM; Sakai K; Tamminga CA Neuropsychopharmacology; 1998 Nov; 19(5):428-33. PubMed ID: 9778664 [TBL] [Abstract][Full Text] [Related]
2. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Sakai K; Gao XM; Hashimoto T; Tamminga CA Synapse; 2001 Feb; 39(2):152-60. PubMed ID: 11180502 [TBL] [Abstract][Full Text] [Related]
3. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Hashimoto T; Ross DE; Gao XM; Medoff DR; Tamminga CA Psychopharmacology (Berl); 1998 May; 137(2):107-12. PubMed ID: 9629996 [TBL] [Abstract][Full Text] [Related]
4. Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Gao XM; Cooper T; Suckow RF; Tamminga CA Neuropsychopharmacology; 2006 Sep; 31(9):1864-8. PubMed ID: 16319911 [TBL] [Abstract][Full Text] [Related]
5. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Naidu PS; Kulkarni SK Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040 [TBL] [Abstract][Full Text] [Related]
6. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569 [TBL] [Abstract][Full Text] [Related]
8. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats. Shireen E; Naeem S; Inam QU; Haleem DJ Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196 [TBL] [Abstract][Full Text] [Related]
9. Effect of chronic olanzapine treatment on striatal synaptic organization. Roberts RC Synapse; 2001 Jan; 39(1):8-15. PubMed ID: 11071704 [TBL] [Abstract][Full Text] [Related]
10. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433 [TBL] [Abstract][Full Text] [Related]
11. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia. Bachus SE; Yang E; McCloskey SS; Minton JN Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat. McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413 [TBL] [Abstract][Full Text] [Related]
13. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia. An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817 [TBL] [Abstract][Full Text] [Related]
14. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. Guzen FP; Cavalcanti JRLP; Cavalcanti DMLP; de Sales LGP; da Silva MSM; da Silva ANA; Pinheiro FI; de Araújo DP Curr Protoc Neurosci; 2019 Jun; 88(1):e68. PubMed ID: 31216395 [TBL] [Abstract][Full Text] [Related]
15. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. Gao XM; Kakigi T; Friedman MB; Tamminga CA J Neural Transm Gen Sect; 1994; 95(1):63-9. PubMed ID: 7857587 [TBL] [Abstract][Full Text] [Related]
16. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184 [TBL] [Abstract][Full Text] [Related]
17. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Sadan O; Bahat-Stromza M; Gilgun-Sherki Y; Atlas D; Melamed E; Offen D Clin Neuropharmacol; 2005; 28(6):285-8. PubMed ID: 16340385 [TBL] [Abstract][Full Text] [Related]
18. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147 [TBL] [Abstract][Full Text] [Related]
19. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Bishnoi M; Chopra K; Kulkarni SK Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680 [TBL] [Abstract][Full Text] [Related]